A number of studies to date have shown elevated levels of IL-17 in the serum or tissues of MS patients, and it has also been established that IL-17 deficiency or blockade has a beneficial effect in EAE, but to varying degrees [8,28]. The gene discussed is IL17A; the disease is myeloid sarcoma.